{
    "organizations": [],
    "uuid": "5a7cb8d00de7e19606eb8a61b96492e2b93fd79f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hemispherx-announces-pricing-of-25/brief-hemispherx-announces-pricing-of-2-57-million-registered-direct-offering-at-a-premium-to-market-idUSASC09WOR",
    "ord_in_thread": 0,
    "title": "BRIEF-Hemispherx Announces Pricing Of $2.57 Million Registered Direct Offering At A Premium To Market",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20 (Reuters) - Hemispherx Biopharma Inc:\n* HEMISPHERX ANNOUNCES PRICING OF $2.57 MILLION REGISTERED DIRECT OFFERING AT A PREMIUM TO MARKET\n* HEMISPHERX BIOPHARMA INC - UNDER TERMS OF PURCHASE AGREEMENT, HEMISPHERX HAS AGREED TO SELL ABOUT 6.6 MILLION SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage: (Reporting by Deepak Devalapur)\n ",
    "published": "2018-04-20T22:23:00.000+03:00",
    "crawled": "2018-04-21T18:12:54.046+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "hemispherx",
        "biopharma",
        "inc",
        "hemispherx",
        "announces",
        "pricing",
        "million",
        "registered",
        "direct",
        "offering",
        "premium",
        "market",
        "hemispherx",
        "biopharma",
        "inc",
        "term",
        "purchase",
        "agreement",
        "hemispherx",
        "agreed",
        "sell",
        "million",
        "share",
        "common",
        "stock",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "deepak",
        "devalapur"
    ]
}